OBJECTIVES: Aortic valve replacement (AVR) in geriatric patients (>75 years) with small aortic roots is a challenge. Patient-prosthesis mismatch and the long cross-clamp time necessary for stentless valves or root enlargement are matters of concern. We compared the results of AVR with sutureless valves (Sorin Perceval), against those with conventional biological valves.
INTRODUCTION
Since 1960 when the first operation was performed, aortic valve replacement (AVR) has been the gold standard for the treatment of symptomatic aortic valve stenosis. Although various valves have been designed, the basic technique has remained similar. After the diseased native aortic valve is removed, the new valve prosthesis is anchored in the aortic annulus with the help of sutures under extracorporal circulation (ECC) and cross-clamping of the aorta. A significant part of the cross-clamp time is spent in placing these sutures in the aortic annulus and the valve prosthesis and then tying the knots. The conventional valves have a sewing ring for this purpose. Therefore, for any given valve size, at least some part of the external valve area is taken up by this sewing ring. This may lead to patient-prosthesis mismatch (PPM), particularly in patients with small aortic roots. Rahimtoola [1] first described this condition, in which the effective orifice area (EOA) of the impacted prosthesis may be inadequate for the patient's body size. This means that patients undergoing AVR for aortic valve stenosis need a valve prosthesis of an adequate size to avoid a possible patient-prosthesis mismatch (PPM) phenomenon.
In recent years, due to the ageing population, the incidence of aortic valve stenosis has increased. A majority of these geriatric patients are females of small stature with corresponding small aortic roots. Several authors have suggested that PPM may be associated with less regression of left ventricular hypertrophy and lower survival [2] . Although some other authors such as Blackstone et al. [3] have disputed this suggestion, surgeons have tried to avoid PPM with various options in patients with small aortic roots by the following means:
(i) Implantation of stentless valves.
(ii) Full root replacement either with homograft, porcine grafts or the so-called Ross operation. (iii) Implantation of a bigger-sized prosthesis after aortic root enlargement (ARE).
Both stentless valve implantation and aortic root replacements are technically more challenging than isolated AVR with conventional stented valves. Although these techniques may result in better haemodynamics, they are not widely used. ARE to implant a larger-sized prosthesis has been described by several surgeons [4] [5] [6] . However, many surgeons are still reluctant to use these techniques routinely. There have also been conflicting reports about the risks associated with these techniques [7, 8] . Moreover, Kulik et al. [9] reported that although ARE is a safe procedure, it does not appreciably improve long-term clinical outcome. All these above-mentioned techniques do prolong the cross-clamp and cardiopulmonary bypass (CPB) times even in experienced hands.
Recently, sutureless valves have been proposed as an ideal solution for this subset of patients [10] . As these valves do not need to be 'sutured', shorter cross-clamp and CPB times are potentially possible. Moreover, due to the absence of a sewing ring, these valves are also almost 'stentless', with a greater valve EOA for any given size. This may therefore result in better haemodynamics even without the root enlargement.
In this study, we compared the perioperative and mid-term follow-up results of AVR with sutureless valves (Sorin Perceval), against those with conventional biological valves in geriatric patients (>75 years) with small aortic roots (<22 mm).
MATERIALS AND METHODS
Between April 2007 and December 2012, 120 isolated AVR were performed in geriatric patients with small annulus (<22 mm) at our centre. Seventy patients (68 females, age 77.4 ± 5.5 years) received conventional stented biological valves (C group). An additional 50 patients (47 females, age 79.8 ± 4.5 years), fulfilling the inclusion and exclusion criteria for a European, multicentre, prospective, non-randomized, clinical feasibility trial, received the Perceval S sutureless aortic valve prosthesis (P group). The Logistic EuroSCRORE of patients in the C group was 16.7 ± 10.4 and that of the P group 20.4 ± 10.7, (P = 0.0054). Minimal-access surgery was performed in 4.3% (3/70) patients in the C group and 72% (36/50) patients in the P group, (<0.001). Patient characteristics are listed in Table 1 . All patients involved in the Perceval trial also gave informed consent. Approval for this study was granted by the Institutional Review Board of our University Hospital.
Statistical analysis
All data analyses were performed with IBM SPSS Statistic 20 for Windows (IBM Corporation, 1 New Orchard Road, Armonk, New York, NY, USA). The most continuous variables were normally distributed. They were expressed as mean with standard deviation. The not normally distributed variables were expressed as median. Statistical comparisons were made by independent-samples T-test, one-way analysis of variance, Mann-Whitney U-test, Kruskal-Wallis H-test, Pearson χ 2 -test, Fisher's exact test depending on the scale level, the distribution and the number of groups. Cox-regression was chosen for univariate and multivariate prognostic analysis of mid-time survival. Prognostic variables of postoperative death within 30 days and hospital stay were evaluated by logistic regression. A value of P < 0.05 was considered significant.
RESULTS
Perioperative data are presented in Table 2 . The Kaplan-Meier survival curve is shown in Fig. 1 . The follow-up data are given in Table 3 . : n = 6, size 21: n = 44). The rest of the size 21 valves were Carpentier Edwards Perimount (n = 12), St. Judes Epic Supra (n = 4), Medtronic Hancock II Ultra (n = 2) and Medtronic Mosaic Cinch (n = 2). The valves were implanted in a supra-annular position using pledgeted sutures. Thirty-day mortality was 4.3% (n = 3). The causes of death were cardiac in 2 patients and respiratory in 1. The mean gradient and the EOA of the valve prosthesis at discharge were 12.7 ± 4.3 mmHg and 1.5 ± 0.18 cm 2 , respectively. The ICU and hospital stays were 2.0 ± 2.6 days and 15.9 ± 10.9 days. The left ventricular ejection fraction at discharge was 55.2 ± 9.7%.
Follow-up. The mean follow-up time was 32.7 ± 15.5 months.
Two patients were lost to follow-up. The mean gradient and the EOA of the valve prosthesis at follow-up were 15.4 ± 6.3 mmHg and 1.3 ± 0.2 cm 2 , respectively. The left ventricular ejection fraction at follow-up was 60.9 ± 10.3%. The mortalities at 1 year and 3 years were 16.4% (n = 10) and 34.3% (n = 12), respectively. One patient developed prosthesis endocarditis at follow-up. Another patient had a paravalvular leak grade 1.
Perceval group
Perioperative results. The valves were successfully and firmly positioned under visual control in all patients; no death occurred during the procedure. The CPB and cross-clamp times were 58.7 ± 20.9 and 30.1 ± 9 min, respectively. Thirty-day mortality was 0%. The mean operation time was 25.4 ± 30.3 min (full sternotomy: 105.9 ± 13.1 min, ministernotomy: 133.0 ± 31.7 min). Of note, 72% (36/50) of these patients underwent AVR via an upper ministernotomy. The rest of the patients (14/50) underwent AVR via a full median sternotomy.
These patients received either a size 21 mm valve (n = 12) or a size 23 valve (n = 38). The mean gradient and the EOA of the valve prosthesis at discharge were 15.9 ± 5 mmHg and 1.5 ± 0.26 cm 2 , respectively. The ICU and hospital stays were 1.8 ± 1.8 days and 14.1 ± 7.5 days.
Follow-up. The mean follow-up time was 22.7 ± 17.5 months.
Three patients were lost to follow-up. The mean gradient and the EOA of the valve prosthesis at follow-up were 13.6 ± 5.4 mmHg and 1.5 ± 0.25 cm 2 , respectively. The left ventricular ejection fraction at follow-up was 62.2 ± 7.6%. The mortalities at 1 year and 3 years were 13.2% (n = 5) and 39.1% (n = 9), respectively. At follow-up, 3 patients developed prosthesis endocarditis and 4 had Grade 1 leakage without haemolysis.
Comparison of the two groups. Tables 1-3 give an overview of the comparison of the two groups. In short, the preoperative characteristics of the two groups did not differ significantly. The Logistic EuroSCRORE of the C group was 16.7 ± 10.4 and that of the P group 20.4 ± 10.7, respectively (P = 0.054). The cross-clamp times (C group 50.3 ± 14.2 min vs P group 30.1 ± 9.0 min, P < 0.001) and CBP times (C group 75.3 ± 23.0 min vs P group 58.7 ± 20.9 min, P < 0.001) were significantly shorter in the P group. Total operational times also tended to be shorter in the P group, albeit, without reaching statistical significance (C group 141.5 ± 33.5 vs P group 125.4 ± 30.5, P = 0.008). The early postoperative course was comparable in terms of ICU stay, complications, mortality and paravalvular leakages. Mean gradient (C group 12.7 ± 4.3 mmHg vs P group 15.9 ± 5.0 mmHg, n.s) as well as EOA (C group 1.5 ± 0.18 cm 2 vs P group 1.5 ± 0.26 cm 2 , n.s.) did not differ postoperatively.
The follow-up of the C group was significantly longer than the P group (C group 32.7 ± 15.5 months vs P group 22.7 ± 17.5 months, P < 0.002). Mean gradient was comparable during the follow-up time (C group 15.4 ± 6.3 mmHg vs P group 13.6 ± 5.4 mmHg, n.s.). The EOA was significantly higher in the P group compared with the C group (C group 1.3 ± 0.2 vs P group 1.5 ± 0.25, P < 0.001), due to a decrease in EOA in the C group. There were no differences between mortality rates at 1-and 3-year follow-up.
DISCUSSION
Surgical AVR has been the gold standard of treatment in patients with symptomatic aortic valve stenosis [11, 12] . The primary goal of this operation is to alleviate the pressure overload on the left ventricle and allow regression as well as remodelling of the left ventricular mass. Logically, a larger-sized valve would reduce the gradient by a greater margin, leading to greater regression of the hypertrophied left ventricle. A smaller-sized prosthetic valve may result in so-called PPM. Therefore, different options have been proposed for patients with small aortic root presenting for AVR. As discussed above, these options are stentless valves, ARE and even complete aortic root replacement. However, all these options are technically more complex and take longer than isolated 'conventional' AVR with stented valve prostheses. Therefore, these techniques have not been popular with surgeons.
Due to the changing population demographics, the age of the patients presenting for AVR is also increasing. According to the data base of the German Society of Cardiothoracic and Vascular Surgery (GSCTVS), >50% of the patients presenting for cardiac surgery in Germany are above the age of 70 years and >10% are the above the age of 80 [13] . The situation is similar in most of the industrialized countries. A large proportion of these geriatric patients are small women. In addition to the presence of significant comorbidities, these patients are also usually small in stature and have calcified aortic roots. Conventional AVR in these geriatric patients with small and calcified aortic roots present a unique challenge to the surgical community. On the one hand, is the need for implantation of the biggest possible prosthesis to maximize the alleviation of the pressure gradient and, on the other hand is the need to keep the cross-clamp and CPB times as short as possible due to the higher perioperative risks. Due to the second reason, many surgeons implant conventional stented valves and accept the possibility of PPM in such patients. Several studies have shown that better results are obtained with minimal-access AVR compared with full sternotomy patients [14] [15] [16] . However, limited exposure to the operative field increases the technical complexity for the surgeon and is reflected in longer operative times in minimally invasive cases. Moreover, minimal-access AVR is technically even more difficult in these geriatric patients. This may be one of the reasons that only 10% of the isolated AVR in Germany are done via a minimally invasive access as reflected in the database of the GSCTVS [13] . Therefore, there is a need for new options of AVR to treat these patients optimally. The idea of a 'sutureless' valve implantation itself is not new. Magovern and Cromie [17] performed the first implantation of such a valve in 1962. These early sutureless valves were bulky and technically difficult to implant, particularly in a small aortic annulus. Moreover, paravalvular leakage was frequent. Thrombosis and ball variance resulting in poppet failure was a common late occurrence. Due to these reasons, these early sutureless valves fell out of favour [18] . The modern sutureless Perceval valve has overcome these disadvantages. Additionally, these valves may have following advantages:
(i) The absence of anchoring sutures should reduce the crossclamp and consequently ECC times. (ii) The absence of a 'suturing ring' potentially results in increased functional valvular diameter for any given valve size. This may reduce the risks of PPM. (iii) The absence of the need for sutures may potentially make minimal-access AVR technically easier and more reproducible.
Between April 2007 and December 2011, we implanted 100 Perceval sutureless valves as a part of a prospective, European, multicentre, non-randomized, clinical feasibility pilot trial. This trial was performed in three stages with time intervals between them. Only a limited number of Perceval valves were available for the study, so not all patients who fitted the inclusion criteria could be included in the trial. This is the reason for a shorter mean followup time in this group of patients. This study highlights the advantages of the Perceval S self-anchoring valve. It is a technically simple and reproducible alternative to AVR. As the valve does not need to be sutured, the limited exposure is not a disadvantage even in patients with calcified or small aortic roots. The lack of necessity for the valve prosthesis to be anchored with sutures potentially reduces the cross-clamp and CPB times. This valve may enable a broader application of minimally invasive AVR. Further longer-term experience is needed to determine the potential clinical benefits and durability of the Perceval S self-anchoring valve.
CONCLUSION
In summary, the data presented here highlight the advantages of the Perceval S sutureless valve in geriatric patients with small aortic roots both in the short-as well as mid-term. Furthermore, this device appears to be ideal for patients with severe calcification of the aortic roots. Further experience is needed to determine the potential clinical benefits of these sutureless valves.
LIMITATIONS
The main limitation of this study is that it is not a prospective randomized study. Another limitation is that the patient cohorts are small. The third limitation is that the Perceval valves were implanted only by two senior surgeons while AVRs with conventional valves were done by all of the staff surgeons, including the two senior surgeons.
Funding
The institution received an unrestricted research grant from Sorin for the conduct of the study.
APPENDIX. CONFERENCE DISCUSSION
Dr U. Lockowandt (Stockholm, Sweden): When you operate on elderly ladies with small aortas, you have several problems. One could be the valve, another problem could be the ascending aorta, which could be small and very calcified. I wonder, if you do a Perceval stentless implantation, is there any possibility of making the aortic incision smaller in order to place it far down or far up if you find a place with less calcification, or perhaps even asymmetrical, left or right, if you can find places with less calcification?
Secondly, I don't know what it is like in Hannover, but in Sweden health care is on a very tight fiscal budget. As alluded to earlier, the introduction of new techniques is difficult if they are more costly. Have you done any cost comparisons between the conventional and the stentless solutions?
Dr Shrestha: In answer to the first question, the Perceval is a sutureless valve. Because of the stent above the leaflets, the aortotomy has to be done a little bit higher, and we use a transverse aortotomy and, because the valve is collapsed and mounted, you see all around. You don't need to do a total transection of the aorta, just a small incision. If the ascending aorta is very calcified, you can always find a place where you can cut, because you don't need to put the sutures all around. Technically it is a lot easier with this valve.
Concerning your second question, of course you are right. In my previous talk I also said that the limiting factor right now is the cost. We hope that it will go down in the future. That is why, at least in Hannover, we are putting this valve in only very old patients, because in the younger age patient the cost is also a factor. If the cost comes down, I think that this valve will be implanted in even more patients. I read with great interest the paper by Shrestha et al. regarding the use of the sutureless Perceval S valve (Sorin Group, Saluggia, Italy) in the elderly with small aortic annulus [1] . The most important change in the present study is likely the introduction of a control group, which had been woefully lacking in the earlier trials assessing exclusively the safety and efficacy of this relatively new aortic valve bioprosthesis [2] [3] .
The authors compared the results of aortic valve replacement using the sutureless Perceval S valves against those with conventional bioprostheses. Although patients in the sutureless valves group had higher Logistic EuroSCORE than patients in the conventional valves group, they showed after 3 years of follow-up that there were no differences in mortality rates between the 2 groups. Furthermore, the mean gradient across the bioprostheses was comparable during the follow-up period. Considering this, it can be questioned whether the method used by the authors to compare these bioprostheses should really be considered the best approach to answer their question? I would like to take the opportunity to rephrase the question that needs to be resolved: after Perceval implantation, do patients with a small aortic annulus exhibit less patient-prosthesis mismatch (PPM) than patients treated conventionally? I think that the article by Shrestha et al. will add substantially valuable data if the incidence of severe PPM is evaluated in each treated group.
Recently, D'Onofrio et al. [4] conducted a propensity-matched multicentre study to compare echocardiographic and clinical outcomes in high risk patients with severe aortic valve stenosis undergoing transapical transcatheter aortic valve implantation (TAVI) using the Edwards Sapien bioprosthesis versus patient undergoing sutureless aortic valve replacement using the Perceval S valve. They showed that in this subset of high risk patients, the Perceval S valve is as safe and effective as a transapical TAVI, and that the higher incidence of paravalvular leak in the TAVI group casts a shadow on the overall benefit of the latter technique.
Another established advantage of using the Perceval S aortic valve is the reduction of cross-clamp and cardiopulmonary bypass times [3] . Aortic cross-clamp duration plays an important role in patient outcomes because it has been demonstrated to be an independent predictor of 30-day mortality after cardiac surgery. More recently, the merit of Perceval S valve has been reiterated by Santarpino et al. [5] in a comparative study. Despite the higher surgical risk, patients with a Perceval S bioprosthesis required less blood transfusion, shorter intubation time and intensive care unit stay than patients in the conventional group.
Even though, the high cost of the Perceval S is not to be dismissed, in the current era of stringent budget, one should consider implanting this valve in patients who are at high risk for surgical aortic valve replacement but who are not actually inoperable.
